Calliditas Therapeutics initiates Phase 3 NEFIGARD trial for Nefecon to treat IgA nephropathy
Swedish pharmaceutical company Calliditas Therapeutics has initiated the Phase 3 NEFIGARD trial to evaluate its lead drug candidate, Nefecon, for treating IgA nephropathy (IgAN), commonly known as Berger’s disease. The NEFIGARD trial marks a significant step for Calliditas Therapeutics as it begins enrolling patients for a late-stage study designed to assess the effectiveness of Nefecon […]